Reminder: Transgenomic to Hold Second Quarter Financial Results Conference Call on August 6, 2013
August 06 2013 - 11:04AM
Business Wire
Transgenomic, Inc. (OTC/BB: TBIO) today announced the
following Webcast:
What:
Transgenomic, Inc. Second Quarter 2013 Financial Results and
Business Update Conference Call
When:
Tuesday, August 6, 2013 @ 5:00 p.m. Eastern
Where:
http://www.transgenomic.com/calendar/2013/07/second-quarter-financial-results-conference-call-august-6-2013
How:
Live over the Internet -- Simply log on to the web at the address
above.
Contact:
Investor Relations, 402-452-5416
To access the call via telephone, dial 866-952-7534 from the
U.S. and Canada or 785-424-1835 for international participants and
enter conference ID TRANS. A telephone replay will be available
from 8:00 p.m. Eastern Time on August 6, 2013 through 11:59 p.m.
Eastern Time on August 20, 2013 by dialing 800-839-3020 (domestic)
or 402-220-7234 (international).
About Transgenomic, Inc.
Transgenomic, Inc. (www.transgenomic.com) is a global
biotechnology company advancing personalized medicine in
cardiology, oncology, and inherited diseases through its
proprietary molecular technologies and world-class clinical and
research services. The Company is a global leader in cardiac
genetic testing with a family of innovative products, including its
C-GAAP test, designed to detect gene mutations which indicate
cardiac disorders, or which can lead to serious adverse events.
Transgenomic has three complementary business divisions:
Transgenomic Clinical Laboratories, which specializes in molecular
diagnostics for cardiology, oncology, neurology, and mitochondrial
disorders; Transgenomic Pharmacogenomic Services, a contract
research laboratory that specializes in supporting all phases of
pre-clinical and clinical trials for oncology drugs in development;
and Transgenomic Diagnostic Tools, which produces equipment,
reagents, and other consumables that empower clinical and research
applications in molecular testing and cytogenetics. Transgenomic
believes there is significant opportunity for continued growth
across all three businesses by leveraging their synergistic
capabilities, technologies, and expertise. The Company actively
develops and acquires new technology and other intellectual
property that strengthens its leadership in personalized
medicine.
Investor Contact:Argot PartnersDavid Pitts,
212-600-1902david@argotpartners.comorCompany
Contact:Transgenomic, Inc.Investor Relations,
402-452-5416investorrelations@transgenomic.com
Telesis Bio (PK) (USOTC:TBIO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Telesis Bio (PK) (USOTC:TBIO)
Historical Stock Chart
From Dec 2023 to Dec 2024